Evotec SE, together with Yonsei University and the Korean biotech company Zymedi, will receive a $4.5 million grant from the Korea Institute of Advanced Technology (KIAT) to fund the development of first-in-class biologic therapies to treat lung diseases, including asthma and idiopathic pulmonary fibrosis (IPF). The project will focus on the preclinical development of novel anti-inflammatory and anti-fibrotic antibodies directed against tRNA synthetases, an emerging therapeutic target class t...